Search

In patients with baseline values <=58 mmol/mol, HbA1c levels did not change, but in patients with baseline values >58 mmol/mol, HbA1c levels significantly decreased after 6 (3 mmol/mol; I P i = 0.006), 12 (1.5 mmol/mol; I P i = 0.013) and 24 months (2 mmol/mol; I P i = 0.017). Keywords: continuous glucose monitoring (CGM); CSII; insulin pump therapy; realworld evidence; type 1 diabetes EN continuous glucose monitoring (CGM) CSII insulin pump therapy realworld evidence type 1 diabetes 1101 1105 5 03/08/23 20230401 NES 230401 INTRODUCTION The MiniMed™ 670G insulin pump was the first hybrid closed-loop (HCL) system available for clinical use. A retrospective analysis of 24-month real-world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pump At baseline, HbA1c was 55 mmol/mol (50-62 mmol/mol), higher than at 6 months (53 mmol/mol [48-60 mmol/mol]; I P i = 0.005) and 12 months (54 mmol/mol [49-63 mmol/mol]; I P i = 0.042), but not different from the values at 18 months (52 mmol/mol [51-64 mmol/mol]) and 24 months (56 mmol/mol [51-64 mmol/mol]; Figure S1). [Extracted from the article]